Anifrolumab, AstraZeneca Plc’s experimental treatment for lupus, has missed its primary endpoint in a study. The drug failed to meet the goal of a late-stage trial that had 373 patients. Patients in the study did not see a statistically significant reduction in disease activity compared with those who received a placebo in the yearlong study, … Continue reading “AstraZeneca’s Experimental Lupus Treatment Fails to Hit Primary Endpoint”
